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Research has established that a relationship exists between an individual’s out-of-pocket (OOP) medica-tion costs and drug utilization.1-4 As OOP drug costs 
increase, individuals are less likely to visit pharmacies and 
increasingly likely to delay or forgo filling their medications.1-4 
The federal government’s introduction of Medicare Part D 
provided seniors aged 65 years and older and other eligible 
beneficiaries a unique opportunity to enroll in a prescription 
drug plan. Following introduction of the Part D benefit in 
2006, beneficiary drug utilization increased by 7%, and OOP 
costs decreased by 16%, a testament to the program’s success.5
While Part D offsets prescription medication costs for many, 
shortcomings remain in this federally directed program. Since 
its inception in 2006, most Part D plans have had a period 
during which the beneficiary is solely responsible for the 
majority of prescription drug costs. This is called the coverage 
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ABSTRACT
BACKGROUND: The substitution of generic treatment alternatives for 
brand-name drugs is a strategy that can help lower Medicare beneficiary 
out-of-pocket costs. Beginning in 2011, Medicare beneficiaries reaching 
the coverage gap received a 50% discount on the full drug cost of brand-
name medications and a 7% discount on generic medications filled during 
the gap. This discount will increase until 2020, when beneficiaries will be 
responsible for 25% of total drug costs during the coverage gap.
OBJECTIVE: To examine the cost variability of brand and generic drugs 
within 4 therapeutic classes before and during the coverage gap for each 
2011 California stand-alone prescription drug plan (PDP) and prospective 
coverage gap costs in 2020 to determine the effects on beneficiary out-of-
pocket drug costs.
METHODS: Equivalent doses of brand and generic drugs in the following 
4 pharmacological classes were examined: angiotensin II receptor block-
ers (ARBs), bisphosphonates, HMG-CoA reductase inhibitors (statins), and 
proton pump inhibitors (PPIs). The full drug cost and patient copay/coinsur-
ance amounts during initial coverage and the coverage gap of each drug 
was recorded based on information retrieved from the Medicare website. 
These drug cost data were recorded for 28 California PDPs.
RESULTS: The highest cost difference between a brand medication and 
a Centers for Medicare & Medicaid Services (CMS)-suggested generic 
treatment alternative varied between $110.53 and $195.49 at full cost and 
between $51.37 and $82.35 in the coverage gap. The lowest cost differ-
ence varied between $38.45 and $76.93 at full cost and between -$4.11 
and $18.52 during the gap.
CONCLUSION: Medicare beneficiaries can realize significant out-of-pocket 
cost savings for their drugs by taking CMS-suggested generic treatment 
alternatives. However, due to larger discounts on brand medications made 
available through recent changes reducing the coverage gap, the potential 
dollar savings by taking suggested generic treatment alternatives during 
the gap is less compelling and will decrease as subsidies increase.
J Manag Care Pharm. 2014;20(3):283-90
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RESEARCH
•	In	 accordance	with	 the	 Patient	 Protection	 and	 Affordable	 Care	
Act signed in March 2010, Medicare beneficiaries will receive a 
graduated manufacturer-paid point-of-sale discount on formu-
lary covered brand-name medications when filled during the 
coverage gap effective in 2011.
What is already known about this subject
•	Additionally,	 a	 beneficiary’s	 Part	 D	 plan	 will	 also	 provide	 a	
discount for generic medications filled during the coverage gap 
effective in 2011.
•	The	 coverage	 gap	 discount	 for	 both	 brand-name	 and	 generic	
medications will increase until 2020, when beneficiaries will be 
responsible for 25% of total drug costs during the coverage gap.
•	Angiotensin	II	receptor	blockers	(ARBs),	bisphosphonates,	HMG-
CoA	 reductase	 inhibitors	 (statins),	 and	 proton	 pump	 inhibitors	
(PPIs)	 are	 4	 highly	 utilized	 drug	 classes	 by	 Medicare	 benefi-
ciaries; each of these classes contain therapeutically equivalent 
brand and generic medications.
•	The	 out-of-pocket	 cost	 variability	 of	 4	 drug	 classes	 (ARBs,	
bisphosphonates,	 statins,	 and	 PPIs)	 during	 initial	 coverage	 and	
the coverage gap was summarized for each stand-alone prescrip-
tion	drug	plan	available	in	California	in	2011.
•	With	 only	 1	 exception,	 out-of-pocket	 costs	 for	 generic	 medi-
cations remained less expensive alternatives to brand-name 
medications, despite a larger subsidy for brand-name medications 
during the coverage gap in 2011.
•	We	demonstrated	that	beneficiary	costs	may	decrease	in	the	cov-
erage gap from the original Medicare coverage level, while placing 
more financial pressure on the plans to incentivize patients.
What this study adds
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adherence to oral hypoglycemic agents by 10.3%, antihyper-
tensive agents by 5.4%, and statins by 1.9%.4	Clearly,	reduced	
adherence to long-term medications increases the likelihood of 
significant and costly clinical events that ultimately increase 
total health care costs.2-4
While there is little, if anything, beneficiaries can do to 
lower manufacturer-set medication prices, increasing pre-
scriber awareness of medication costs may be an integral step 
in decreasing cost-related drug nonadherence. Prescriber 
knowledge regarding medication costs was examined in a 
survey-based study among 210 general practitioners. Of those 
surveyed, 43% were found to have limited, if any, knowledge of 
drug costs.8 Furthermore, the study suggested that prescribers 
with inaccurate drug cost estimates were less likely than other 
prescribers to exercise therapeutic substitution.8
A lack of effective communication also exists between pre-
scribers and patients with regards to concerns of medication 
affordability. A survey of 17,569 Medicare beneficiaries in 2003 
revealed that 26.3% had cost-related medication nonadher-
ence.9 Of those, 61% expressed concerns about their medica-
tion costs to their physicians, and only 38.1% were switched 
to a cheaper alternative by their physicians.9	 In	a	nationwide	
survey of adults with chronic illnesses who admitted to cost-
related medication underutilization, two-thirds claimed never 
discussing planned cost-related underuse with their physi-
cians, and over half did not believe their providers could help.10 
Even when patients discussed medication costs with their 
physicians, fewer than 1 in 3 said their physicians made any 
attempt to address their cost-related concerns.10 
Another aspect to this issue involves patients’ willingness to 
pay more for brand-name medications. A survey of members 
in a large managed care organization in the western United 
States was conducted, and participants with a chronic dis-
ease (i.e., hypertension, diabetes, dyslipidemia, arthritis, or 
gastroesophageal reflux disease) were asked if they would be 
willing	to	pay	extra	for	a	brand-name	medication.	Half	of	the	
respondents were willing to pay extra, even if a generic equiva-
lent was available.11	However,	there	appeared	to	be	a	financial	
threshold, as a majority indicated reluctance to pay more than 
an additional $10 per month for a brand-name medication, 
when a less expensive alternative was available.11
While some patients may desire brand-name drugs, OOP 
costs	 can	 be	 a	 contributing	 factor	 to	 adherence.	Claims	 data	
for new prescriptions of generic or brand-only drug therapy 
were analyzed for medication adherence among patients with 
specific	 medical	 conditions.	 Generic	 drugs	 were	 associated	
with significantly greater adherence than brand-name drugs in 
patients with hypercholesterolemia (62% vs. 53%) but surpris-
ingly significantly lower adherence in patients with hyperten-
sion (47% vs. 59%).12 No significant difference in adherence 
rates between generic and brand medications was found for 
the other investigated conditions, including seizure disorders, 
hypothyroidism, and type 2 diabetes.12 The study authors did 
gap and is commonly referred to as the “donut hole.” The cov-
erage gap starts after beneficiaries and their plans have spent 
a predetermined amount on formulary covered drugs.6 Prior 
to 2010, most beneficiaries were required to pay 100% of their 
prescription medication costs when filled during the donut 
hole.7	Higher	OOP	medication	 costs	 can	be	 a	major	problem	
for those beneficiaries with limited income and resources.1,3,4 
Moreover, research has shown that a beneficiary’s inability to 
afford medications during the donut hole can be linked to such 
problematic medication behaviors as skipping doses, delaying 
refills, using medications less frequently, stopping medications, 
or going without certain basic necessities (e.g., food or rent) in 
order to afford medications.1 Medication adherence has been 
shown to be negatively correlated with patients’ OOP costs.2-4 
Taira et al. (2006) reported that medication adherence 
decreased as drug copayments increased among patients with 
hypertension taking at least 1 antihypertensive medication.2	In	
this study, patients were deemed to be adherent to their anti-
hypertensive medications if their medication possession ratio 
was > 80%. Using this definition of adherence, the odds ratio 
(OR) for adherence was 0.76 with a $5 copayment; however, 
with higher copayments (ranging from $20-$165), the OR for 
adherence dropped to 0.48. Results suggested that the copay-
ment amount is a strong predictor of patient adherence.2 The 
same	 pattern	 emerged	 with	 respect	 to	 HMG-CoA	 reductase	
inhibitors (statins)—lower patient copayments were positively 
correlated with higher levels of medication adherence.3 A $10 
increase in copayments for statins was associated with a 1.8% 
reduction in adherence for new users and a 3% reduction in 
adherence for continuing users.3 This finding suggests adop-
tion of lower copayments may increase medication adherence 
and should therefore be considered by plan administrators.3 
Another study found that medication adherence in patients 
decreased following a $5 systemwide increase in copayments 
at Veterans Affairs medical centers.4 The long-term effect of 
this nominal copayment change was a decrease in veterans’ 
Year Brand Drugs (%) Generic Drugs (%)
2006-2009 100 100











TABLE 1 Beneficiary Cost Responsibilities 
in the Gap14
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not identify any concrete reasons for these results but did find 
that $0 copayment amounts were related to increased medica-
tion adherence regardless of the individual’s medical condition 
or whether the medication in question was generic or brand.12 
These findings may indicate that any OOP costs may decrease 
adherence. 
Starting in 2011, in accordance with the Patient Protection 
and	Affordable	Care	Act,	Medicare	beneficiaries	received	a	50%	
manufacturer-paid point-of-sale copay discount off the total 
cost of the drug on formulary covered brand-name medications 
when filled during the coverage gap.13 Additionally, in 2011, 
a beneficiary’s Part D plan discounted generic medications 
by 7% of the total drug cost, when filled during the cover-
age gap.6 To date, no studies have examined the cost differ-
ence between brand-name medications and suggested generic 
treatment alternatives during the coverage gap under Part D. 
This coverage gap discount is set to increase until 2020, when 
beneficiaries will be responsible for 25% of total drug costs for 
both brand and generic medications (Table 1). Manufacturers 
will still be responsible for 50%, and the Part D plan will then 
Druga
 $ in SBP/DBP (mm Hg)b
7-8/4-5 8-10/5-6 10-12/6-7 12-13/7-8
Candesartanc 
(n = 7)
Dose 4 mg 8 mg 16 mg 32 mg
Total drug cost ($)  71.97 (4.19)  71.97 (4.19)  71.97 (4.19)  71.97 (4.19)
Initial	coverage	($)  57.57 (22.15)  57.57 (22.15)  57.57 (22.15)  57.57 (22.15)
Coverage	gap	($)  36.95 (2.04)  36.95 (2.04)  36.95 (2.04)  36.95 (2.04)
2020 gap ($)  17.99 (1.05)  17.99 (1.05)  17.99 (1.05)  17.99 (1.05)
Eprosartanc 
(n = 4)
Dose  400 mg 600 mg  
Total drug cost ($)   90.85 (5.07)  106.10 (5.87)  
Initial	coverage	($)   83.88 (4.66)  83.88 (4.66)  
Coverage	gap	($)   46.21 (2.68)  53.80 (3.08)  
2020 gap ($)   22.71 (1.27)  26.53 (1.47)  
Irbesartanc 
(n = 10)
Dose  75 mg 150 mg 300 mg
Total drug cost ($)   78.06 (3.83)  82.08 (4.04)  98.24 (4.87)
Initial	coverage	($)   39.32 (24.25)  40.09 (24.69)  41.74 (23.81)
Coverage	gap	($)   40.00 (1.93)  42.00 (2.03)  50.09 (2.42)
2020 gap ($)   19.52 (0.96)  20.52 (1.01)  24.56 (1.22)
Losartan 
(25 mg: n = 26;  
50 mg and  
100 mg: n = 27)
Dose 25 mg 50 mg 100 mg  
Total drug cost ($)  20.30 (11.84)  25.36 (15.31)  33.60 (21.86)  
Initial	coverage	($)  6.23 (5.17)  6.36 (5.67)  6.75 (6.10)  
Coverage	gap	($)  17.34 (11.33)  21.28 (14.80)  28.12 (21.09)  
2020 gap ($)  5.08 (2.96)  6.34 (3.83)  8.40 (5.46)  
Olmesartanc 
(n = 11)
Dose  5 mg 20 mg 40 mg
Total drug cost ($)   67.23 (3.08)  81.74 (3.78)  113.04 (5.32)
Initial	coverage	($)   38.29 (16.16)  42.68 (19.77)  49.96 (19.53)
Coverage	gap	($)   34.64 (1.58)  41.63 (2.43)  57.55 (2.62)
2020 gap ($)   16.81 (0.77)  20.43 (0.95)  28.26 (1.33)
Telmisartanc 
(n = 18)
Dose  20 mg 40 mg 80 mg
Total drug cost ($)   99.37 (4.60)  99.37 (4.60)  99.37 (4.60)
Initial	coverage	($)   43.53 (22.81)  43.53 (22.81)  43.53 (22.81)
Coverage	gap	($)   50.57 (2.62)  50.57 (2.62)  50.57 (2.62)
2020 gap ($)   24.84 (1.15)  24.84 (1.15)  24.84 (1.15)
Valsartanc 
(40 mg and  
320 mg: n = 27;  
80 mg and  
160 mg: n = 26)
Dose 40 mg 80 mg 160 mg 320 mg
Total drug cost ($)  130.80 (23.91)  81.88 (3.34)  87.89 (3.58)  110.61 (4.41)
Initial	coverage	($)  42.71 (16.03)  35.76 (13.16)  37.46 (14.25)  40.57 (16.29)
Coverage	gap	($)  68.71 (2.94)  41.89 (1.98)  44.89 (2.09)  56.26 (2.46)
2020 gap ($)  32.70 (5.98)  20.47 (0.84)  21.97 (0.90)  27.65 (1.10)
an indicates number of PDPs with medication on plan formulary.
bBlood pressure decrease based on Medicare Plan Finder Tool equivalency tables and package insert data.
cIndicates drug was available brand only at the time of data pull.
ARB = angiotensin II receptor blockers; DBP = diastolic blood pressure; mg =milligram; mm Hg = millimeter of mercury; PDP = prescription drug plan; SBP = systolic blood 
pressure; SD = standard deviation.
TABLE 2 ARBs: Average (SD) Costs of Brand-Name Medications and Suggested 
Generic Treatment Alternatives Under 2011 California PDPs
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be responsible for the remaining 25% of total brand drug costs 
during the gap.14 This cost-sharing arrangement means that 
plans and beneficiaries will both have the same “skin in the 
game” during the coverage gap.
In	 this	study,	we	analyzed	beneficiary	cost	data	of	various	
suggested generic treatment alternatives. The objective of the 
present research was to determine cost disparities of brand-
name medications and equipotent suggested generic treatment 
alternatives during the coverage gap for drugs in 4 pharma-
cological	 classes:	 angiotensin	 II	 receptor	 blockers	 (ARBs),	
bisphosphonates,	HMG-CoA	reductase	inhibitors	(statins),	and	
proton	pump	inhibitors	(PPIs).	Additionally,	 the	future	cover-
age gap drug costs in 2020 for beneficiaries and drug plans 
were estimated.
■■  Methods
Four	 pharmacological	 drug	 classes	 (ARBs,	 bisphosphonates,	
statins,	 and	PPIs)	were	 chosen	based	on	high	utilization	pat-
terns by beneficiaries for treatment of common chronic con-
ditions and the presence of suggested alternative brand-only 
and generic medications that existed within each class. Livalo 
(pitavastatin) was available in 2011 but did not have any cost 
data available on the Medicare website during the data collec-
tion period and was therefore excluded from the study. Dose 
equivalence for brand and generic drugs in all 4 classes was 
established using dose equivalency tables from the Medicare 
website and verified through examination of published litera-
ture and drug monographs. 
The data collection period for this cross-sectional observa-
tional study commenced in January 2011 and ended in April 
2011. Drugs from each of the 4 examined classes were entered 
into the Medicare Plan Finder Tool (available at https://www.
medicare.gov/find-a-plan/questions/home.aspx). Alternative 
brand and generic medications were recorded from the Plan 
Finder	 Tool’s	 “Lower	 Your	Drug	Costs”	 link	 available	 on	 the	
Plan Results page. This function is available for certain drugs 
that have alternative medications within the same drug class 
and allows users to view alternative equivalent doses of brand 
and generic medications within the same class and their 
respective costs under each plan. Next, the full drug cost and 
cost during the coverage gap as listed on the Medicare website 
was	 recorded	 for	 all	 2011	 California	 stand-alone	 prescrip-
tion drug plans (PDPs). Although 33 PDPs were available in 
California	in	2011,	data	from	only	28	plans	were	available	on	
the Medicare website during the data collection period. Plan 
drug costs were included in the analysis if the drug was on the 
plan’s formulary.
The beneficiary’s OOP cost during initial coverage and the 
coverage gap listed on the Medicare website for each analyzed 
medication	 was	 averaged	 across	 all	 available	 2011	 California	
PDPs that included it on their formularies. The estimated 2020 
coverage gap cost for both beneficiaries and Part D plans was 
estimated by multiplying each drug’s total cost by 25% and then 
averaging across all PDPs listing it as a formulary medication.
Descriptive statistics were used to summarize drug cost 






(5 mg, 35 mg,  
70 mg: n = 28;  
10 mg: n = 26)
Dose (quantity) 5 mg (30) 10 mg (30) 35 mg (4) 70 mg (4)  
Total drug cost ($)  28.60 (18.48)  25.16 (16.06)  18.76 ($15.80)  18.39 (14.39)  
Initial	coverage	($)  4.95 (3.33)  5.15 (2.99)  4.54 ($3.21)  4.14 (2.72)  
Coverage	gap	($)  21.20 (18.32)  17.82 (15.22)  15.50 ($15.53)  14.39 (14.16)  
2020 gap ($)  7.15 (4.62)  6.29 (4.01)  4.69 ($3.95)  4.60 (3.60)  
Risedronateb 
(n = 16)
Dose (quantity) 5 mg (30)  35 mg (4)  150 mg (1)
Total drug cost ($)  114.47 (3.93)  106.95 (3.67)  115.70 (3.97)
Initial	coverage	($)  61.29 (23.37)  60.49 (24.08)  61.42 (23.26)
Coverage	gap	($)  58.18 (2.07)  54.41 (1.95)  58.79 (2.08)
2020 gap ($)  28.62 (0.98)   26.74 (0.92)   28.92 (0.99)
Ibandronateb 
(n = 23)
Dose (quantity)     150 mg (1)
Total drug cost ($)  115.02 (4.19)
Initial	coverage	($)  42.72 (13.56)
Coverage	gap	($)  58.51 (2.51)
2020 gap ($)      28.76 (1.05)
an indicates number of PDPs with medication on plan formulary.
bIndicates drug was available brand only at the time of data pull.
mg = milligram; PDP = prescription drug plan; SD = standard deviation.
TABLE 3 Bisphosphonates: Average (SD) Costs of Brand-Name Medications and 
Suggested Generic Treatment Alternatives Under 2011 California PDPs
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■■  Results
A	 total	of	7	ARBs	 (candesartan,	eprosartan,	 irbesartan,	 losar-
tan, olmesartan, telmisartan, and valsartan); 3 bisphospho-
nates	 (alendronate,	 ibandronate,	 and	 risedronate);	 6	 PPIs	
(dexlansoprazole, esomeprazole, lansoprazole, omeprazole, 
pantoprazole, and rabeprazole); and 6 statins (atorvastatin, flu-
vastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin) 
were examined. Tables 2-5 highlight the full initial coverage, 
2011 coverage gap, and 2020 coverage gap costs (mean [SD]) 
of brand name and suggested generic treatment alternatives 
under	the	28	available	California	PDPs	in	2011.	
Table 2 reveals that the costs of both candesartan and 
telmisartan were dose independent. Valsartan was unique in 
that the lowest and highest available strengths of the drug are 
more costly than other available strengths. During the coverage 
gap, brand-name drugs cost between $8.83 and $51.37 more 
than suggested generic treatment alternatives. Estimated 2020 
coverage gap costs were lower than current copay amounts 
for	all	ARBs,	except	for	 lostartan	(the	only	ARB	available	as	a	
generic at the time of this study).
Cost	 data	 for	 orally	 administered	 bisphosphonates	 with	
daily, weekly, and monthly dosing regimens are presented in 
Table 3. Minimal cost differences were noted between differ-
ent	dosing	regimens	for	each	medication.	Generically	available	
alendronate 70 milligrams (mg) had the lowest OOP cost dur-
ing the coverage gap in 2011 and as estimated for 2020. For 
all 3 dosing regimens, risedronate had higher average copay/
coinsurance amounts during the initial coverage level than 
during the 2011 or estimated 2020 coverage gap periods. No 
intravenous bisphosphonates were included, since these are 
billed	to	Medicare	Part	B,	not	Part	D.
Equipotent	 doses	 of	 PPIs	 can	 be	 found	 in	 Table	 4.	 The	
total drug cost difference between brands and suggested 
generic treatment alternatives ranged from $41.91 to $195.49. 
During the 2011 donut hole, the lowest cost brand-name drug 
(Dexilant, or dexlansoprazole, 30 mg, average [SD] coinsur-
ance cost of $65.43 [$2.28]) was actually less expensive than 
the highest priced generic alternative (lansoprazole 15 mg, 
average [SD] coinsurance cost of $69.54 [$21.79]). This sce-
nario was found to be true with the higher doses of Dexilant 
(dexlansoprazole) 60 mg and lansoprazole 30 mg, as well. For 
all	 PPIs	 (except	 rabeprazole),	 the	drug	 cost	 or	 copay/coinsur-
ance amounts were similar or identical between the different 
strengths.
Table 5 highlights cost differences for brand and generic 
statins. The full drug cost of statins is largely independent of 
dose, although large price increases are seen with the highest 
doses of fluvastatin and lovastatin and between the lowest 
dose of atorvastatin and all other doses of the drug. The cost 
difference between brand and generic alternatives during the 
coverage	gap	varied	from	$18.52	to	$78.89.	Brand-name	statins	
were estimated to be less expensive during the 2020 coverage 
gap than the 2011 initial coverage copay/coinsurance amounts. 
At the time of this study, atorvastatin was only available as a 
brand-name drug.
■■  Discussion
Our study revealed that the cost disparity between brand 
and generic medications filled prior to the gap is decreased 
considerably once the beneficiary reaches the coverage gap. 
In	2011,	7.9%	of	Medicare	beneficiaries	 reached	 the	coverage	
gap, receiving over $2.3 billion collectively in coverage gap 
discounts.15 The absolute beneficiary cost difference between 
brand-name medications and generic alternatives should con-
tinue to shrink each year (plateauing in 2020), as an increasing 
percentage of a beneficiary’s formulary covered medication 
costs	 are	 subsidized	 during	 the	 gap.	 Beneficiary	 OOP	 gap	
costs for 2020 were estimated in this study and indicated that 
Druga Low Dose High Dose
Dexlansoprazoleb  
(n = 24)
Dose 30 mg 60 mg
Total drug cost ($)  129.14 (4.07)  129.14 (4.07)
Initial	coverage	($)  56.86 (24.21)  56.86 (24.21)
Coverage	gap	($)  65.43 (2.28)  65.03 (3.29)
2020 gap ($)  32.28 (1.02)  32.28 (1.02)
Esomeprazoleb 
(n = 22)
Dose 20 mg 40 mg
Total drug cost ($)  183.98 (8.35)  183.98 (8.35)
Initial	coverage	($)  41.09 (6.74)  41.09 (6.74)
Coverage	gap	($)  92.80 (4.42)  92.80 (4.42)
2020 gap ($)  46.00 (2.09)  46.00 (2.09)
Lansoprazole 
(n = 19)
Dose 15 mg 30 mg
Total drug cost ($)  78.26 (16.39)  74.52 (12.92)
Initial	coverage	($)  24.38 (17.93)  24.35 (17.95)
Coverage	gap	($)  69.54 (21.79)  66.04 (18.91)
2020 gap ($)  19.56 (4.10)  18.63 (3.23)
Omeprazole 
(n = 28)
Dose 20 mg 40 mg
Total drug cost ($)  25.24 (21.30)  29.27 (24.25)
Initial	coverage	($)  5.23 (4.44)  5.54 (4.39)
Coverage	gap	($)  20.56 (21.18)  23.83 (23.83)
2020 gap ($)  6.31 (5.33)  7.32 (6.06)
Pantoprazole 
(n = 14)
Dose 20 mg 40 mg
Total drug cost ($)  69.54 (35.74)  68.48 (34.49)
Initial	coverage	($)  22.08 (23.34)  22.04 (23.33)
Coverage	gap	($)  58.65 (35.77)  58.04 (34.86)




Total drug cost ($)  209.86 (0)
Initial	coverage	($)  92.34 (32.65)
Coverage	gap	($)  106.18 (0)
2020 gap ($)   52.47 (0)
an indicates number of PDPs with medication on plan formulary.
bIndicates drug was available brand only at the time of data pull.
mg = milligram; PDP = prescription drug plan; PPI = proton pump inhibitors; 
SD = standard deviation.
TABLE 4 PPIs: Average (SD) Costs of Brand-
Name Medications and Suggested 
Generic Treatment Alternatives 
Under 2011 California PDPs
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manufacturer to help increase market share. Another possible 
contributor to this finding is that generic lansoprazole became 
available in late 2009, and the cost disparity between the 
brand-name medication (Prevacid) and its generic alternative 
(lansoprazole) may have been at its lowest level at that point 
in time.
The decrease in cost disparity between brand-name medica-
tions and suggested generic treatment alternatives may change 
beneficiary behavior. As previous research has suggested, 
patients are willing to pay nominally more for brand-name 
medications when a cheaper generic alternative is available.11 
Based	 on	 these	 findings,	 one	 could	 infer	 that	 upon	 reaching	
the gap, there may be less financial pressure to switch from 
a higher cost brand-name medication to a less expensive 
generics will still remain less expensive than brand-name med-
ications; however, copay/coinsurance amounts in the 2020 cov-
erage gap were estimated to be lower than current OOP costs 
during the initial coverage phase (generally the least expensive 
coverage level of the Medicare Part D benefit).
As expected, the cost difference between brand-name medi-
cations and equipotent doses of suggested generic treatment 
alternatives	was	far	less	when	filled	during	the	gap.	However,	
unexpectedly, we also found that in 1 instance filling a brand-
name medication (Dexilant [dexlansoprazole]) would have 
been less expensive than filling a suggested generic treatment 
alternative (lansoprazole) during the gap across the examined 
PDPs. This finding may be explained by the late entry of dex-
lansoprazole to the market and the competitive pricing by its 
Druga
% LDL decreaseb
15%-19% 20%-30% 31%-39% 40%-45% 46%-49% 50%-54% 55%+
Fluvastatinc 
(n = 10)
Dose 20 mg 40 mg 80 mg     
Total drug cost ($)  98.15 (4.69)  98.15 (4.69)  190.99 (6.65)  
Initial	coverage	($)  55.95 (24.82)  55.95 (24.82)  63.94 (26.49)  
Coverage	gap	($)  50.03 (2.28)  50.03 (2.28)  96.44 (3.42)  
2020 gap ($)  24.54 (1.17)  24.54 (1.17)  47.75 (1.66)     
Lovastatin 
(10 mg: n = 23;  
20 mg and  
40 mg: n = 25;  
80 mg: n = 26)
Dose 10 mg 20 mg 40 mg 80 mg  
(40 mg BID)
 
Total drug cost ($)  13.56 (7.08)  17.08 (13.28)  24.62 (23.64)  62.60 (71.06)  
Initial	coverage	($)  4.09 (3.05)  4.41 (3.04)  4.71 (3.00)  5.29 (3.53)  
Coverage	gap	($)  11.26 (7.54)  14.32 (13.14)  19.45 (21.68)  52.30 (69.26)  
2020 gap ($)  3.39 (1.77)  4.27 (3.32)  6.15 (5.91)  15.65 (17.77)    
Pravastatin 
(10 mg and  
20 mg: n = 28;  
40 mg and  
80 mg: n = 27)
Dose 10 mg 20 mg 40 mg 80 mg  
Total drug cost ($)  17.99 (17.12)  17.90 (17.50)  22.87 (26.29)  31.36 (24.19)  
Initial	coverage	($)  4.35 (2.96)  4.33 (2.96)  4.38 (2.94)  4.75 (2.99)  
Coverage	gap	($)  15.01 (16.75)  15.03 (16.98)  19.07 (25.48)  24.29 (25.00)  
2020 gap ($)  4.50 (4.28)  4.47 (4.37)  5.72 (6.57)  7.84 (6.05)    
Simvastatin 
(5 mg, 20 mg,  
40 mg: n = 26;  
10 mg: n = 24;  
80 mg: n = 27)
Dose 5 mg 10 mg 20 mg 40 mg 80 mg  
Total drug cost ($)  16.26 (11.69)  17.65 (15.87)  22.01 (28.19)  22.22 (28.04)  22.67 (27.41)  
Initial	coverage	($)  4.01 (2.72)  3.73 (2.76)  3.95 (2.80)  4.08 (2.74)  4.32 (2.88)  
Coverage	gap	($)  12.78 (11.72)  14.35 (15.69)  18.28 (27.16)  18.30 (27.09)  18.65 (26.56)  
2020 gap ($)  4.07 (2.92)  4.41 (3.97)  5.50 (7.05)  5.56 (7.01)  5.67 (6.85)   
Atorvastatinc  
(10 mg, 40 mg,  
80 mg: n = 23;  
20 mg: n = 22)
Dose  10 mg 20 mg 40 mg 80 mg  
Total drug cost ($)   112.18 (14.86)  153.49 (6.31)  153.38 (6.19)  153.38 (6.19)  
Initial	coverage	($)   36.67 (16.10)  40.09 (17.77)  39.66 (17.48)  39.66 (17.48)  
Coverage	gap	($)   57.06 (7.59)  77.62 (3.27)  77.57 (3.21)  77.57 (3.21)  
2020 gap ($)    28.05 (3.72)  38.37 (1.58)  38.35 (1.55)  38.35 (1.55)  
Rosuvastatinc  
(5 mg, 10 mg,  
20 mg: n = 23;  
40 mg: n = 25)
Dose  5 mg 10 mg 20 mg 40 mg
Total drug cost ($)   139.53 (6.07)  139.53 (6.07)  139.53 (6.07)  139.16 (5.95)
Initial	coverage	($)   39.34 (20.87)  39.34 (20.87)  39.34 (20.87)  38.60 (20.20)
Coverage	gap	($)   70.82 (3.08)  70.82 (3.08)  70.82 (3.08)  70.63 (3.18)
2020 gap ($)     34.88 (1.52)  34.88 (1.52)  34.88 (1.52)  34.79 (1.49)
an indicates number of PDPs with medication on plan formulary.
bLDL decrease based on Medicare Plan Finder Tool equivalency tables and package insert data.
cIndicates drug was available brand only at the time of data pull.
BID = twice daily; LDL = low-density lipoprotein; mg = milligram; PDP = prescription drug plan; SD = standard deviation; statin = HMG-CoA reductase inhibitor. 
TABLE 5 Statins: Average (SD) Costs of Brand-Name Medications and Suggested 
Generic Treatment Alternatives Under 2011 California PDPs
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offered	in	California	and	may	not	be	generalizable	nationally.	
Fourth, the estimated coverage gap costs for 2020 do not take 
into account unknown and incalculable changes to brand and 
generic drug prices and are calculated based on 2011 total drug 
costs. We recommend that future studies be conducted to see 
if our results are replicable in the other 33 Medicare regions. 
Lastly, this study does not account for possible discount pro-
grams (e.g., $4 generics) that beneficiaries can utilize to reduce 
OOP costs outside of their PDP benefits. 
These limitations notwithstanding, this is the first study 
known to examine the cost difference between brand-name 
medications and suggested generic treatment alternatives 
during the coverage gap and to estimate the costs to beneficia-
ries and Part D plans when the full discount is implemented 
in 2020.
■■  Conclusions
Medicare beneficiaries can realize significant costs savings by 
taking suggested generic treatment alternatives prior to the 
coverage gap. Additionally, due to larger discounts on brand 
medications, the potential dollar savings by taking suggested 
generic treatment alternatives during the gap is less financially 
compelling from a beneficiary’s perspective, especially as the 
coverage gap subsidy increases in future years. While benefi-
ciary copayment increases indirectly correlate with medication 
adherence rates, current policy and practices may incentivize 
brand-name medication use during the coverage gap, placing 
PDPs at a financial disadvantage when suggested generic treat-
ment alternative medications are available.
suggested generic treatment alternative from the same medica-
tion class. The result of such behavior might be increased and 
unnecessary medications costs that are paid for by private plan 
sponsors and/or the Medicare program. This behavior may 
be enhanced by the low OOP costs observed in the estimated 
2020 coverage gap costs, which were lower than the average 
initial coverage copay/coinsurance amounts for all brand-name 
drugs included in this study, except esomeprazole. This would 
also increase the cost to the PDP, since the plan will be respon-
sible for an equivalent amount (25% of brand-name medica-
tions) during the coverage gap in 2020.
The estimated 2020 coverage gap costs presented in this 
study (Tables 2-5) are the costs to both the beneficiary and the 
PDP.	In	2013	and	2014,	PDPs	become	responsible	for	2.5%	of	
total brand-name drug costs in the coverage gap with a rapid 
increase to 25% by 2020 (Table 1), indicating a financial incen-
tive for plans to keep beneficiaries from reaching the coverage 
gap. This is counter to the lower beneficiary OOP costs during 
the 2020 coverage gap as compared with the 2011 copay/coin-
surance amounts in the initial coverage phase. This opposing 
financial incentive may lead to increased utilization of brand-
name medications during the gap and increased PDP costs if 
patients do not switch to suggested generic alternatives. While 
many of the brand-name medications examined in this study 
have already gone generic at the time of publication, and many 
more will by 2020, the medications included in this study are a 
small sample of the multitude of drug classes that will continue 
to have brand-name only medications. As has been observed 
with premiums in the wake of the Patient Protection and 
Affordable	Care	Act,	the	effects	of	copay/coinsurance	subsidiza-
tion during the coverage gap may cause an increase in benefi-
ciary OOP costs during the initial coverage phase to allow for 
PDPs to recoup the increased expense during the coverage gap.
Future studies examining the fill rates of brand-name medi-
cations and suggested generic treatment alternatives before, 
during, and after the coverage gap would enable assessment 
as to whether beneficiary and/or prescriber behavior changes 
during each of these different phases of the Medicare benefit. 
Using a claims database to retrospectively examine Medicare 
beneficiary adherence and medication switching in response 
to price changes and the impact of generic substitutions would 




included in data collection due to lack of availability of plan 
information for the other 5 plans on the Medicare website. 
Second, the collected data were specific for the changes in 
Medicare being implemented in 2011. Therefore, it is possible 
that the results may differ in subsequent years based on annual 
changes that occur to the Medicare benefit and changes in 
drug costs. Third, the cost data collected were specific for PDPs 
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